Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis (SpeSerTryp)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05466630 |
|
Recruitment Status :
Recruiting
First Posted : July 20, 2022
Last Update Posted : July 20, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Human African Trypanosomiasis Sleeping Sickness Trypanosoma Brucei Gambiense; Infection West African Sleeping Sickness | Diagnostic Test: Serological field test for HAT Diagnostic Test: malaria rapid test Diagnostic Test: Immunologic laboratory tests Diagnostic Test: Molecular laboratory tests | Not Applicable |
In the last decade, the prevalence of Trypanosoma brucei gambiense (Tbg) human African trypanosomiasis (HAT) has fallen and HAT has been targeted for transmission interruption by 2030. To achieve this goal, disease surveillance remains essential and is based on the identification of cases after screening carried out in the field with a serological test.
The SpeSerTryp study is a prospective evaluation of the specificity of serological field tests for the diagnosis of HAT in Côte d'Ivoire and Guinea. Since the prevalence of HAT is low in these countries, sensitivity will not be assessed.
The main objective is to evaluate and compare the specificity of 5 serological field tests: Bioline HAT 2.0 (Abbott, South Korea), HAT Sero-K-SeT & HAT 2.0 Sero-K-SeT (Coris BioConcept, Belgium ), TDR DCN (USA), and the CATT/T.b. gambiense (Institute of Tropical Medicine Antwerp, Belgium). The secondary objectives are: 1° to assess the specificity of the 5 serological field tests according to malaria status; and 2° to compare the performance of immunological laboratory tests (trypanolysis, ELISA/T.b.gambiense, g-iELISA) and molecular laboratory tests (Trypanozoon RT-qPCR multiplex, SNP RT-qPCR and SHERLOCK) as reference tests to differentiate false positive subjects to serological field tests from subjects who had contact with Tbg. Specificity values will be determined against a composite reference test consisting of the most sensitive HAT parasitological methods. SpeSerTryp is a prospective study that will take place in the endemic health districts of Bonon and Sinfra in Côte d'Ivoire and in the endemic health districts of Forécariah, Dubréka and Boffa in Guinea. In each country, 500 participants will be actively recruited by mobile teams. The inclusion criteria are: Age greater than or equal to 10 years and obtaining signed informed consent. The exclusion criteria are: Severe anemia preventing blood sampling; serious illness preventing the obtaining of informed consent and participation in the study; or history of HAT. After obtaining informed consent, a venous blood sample will be taken (6 mL). This specimen will be used to carry out the 5 serological tests for HAT, the RDT for malaria, and for participants with at least one of the 5 serological tests positive, parasitological confirmation of HAT and molecular and immunological laboratory tests . The duration of participant recruitment is estimated to be around 30 days, while laboratory analyses will take about 6 months. HAT cases identified during the study will be treated in accordance with current national guidelines.
This study will be conducted in accordance with the protocol, the current version of the Declaration of Helsinki, ICH-BPC E6/R2 guidelines, and all national legal and regulatory requirements.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1000 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis in Côte d'Ivoire and Guinea |
| Actual Study Start Date : | June 20, 2022 |
| Estimated Primary Completion Date : | August 31, 2022 |
| Estimated Study Completion Date : | April 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
participant
All eligible participants will undergo 5 serological field tests for HAT and a malaria test. Those testing positive in at least 1 serological field test will undergo parasitology to confirm HAT and immunological and molecular laboratory tests
|
Diagnostic Test: Serological field test for HAT
Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
Other Name: Bioline HAT 2.0 (Abbott, South Korea), HAT Sero-K-SeT (Coris BioConcept, Belgium), HAT 2.0 Sero-K-SeT (Coris BioConcept, Belgium), RDT DCN (USA), CATT/Tb gambiense (ITM Antwerp, Belgium) Diagnostic Test: malaria rapid test RDT detecting HRP2 plasmodium antigen. Diagnostic Test: Immunologic laboratory tests Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
Other Name: trypanolysis, ELISA/T.b.gambiense, g-iELISA Diagnostic Test: Molecular laboratory tests Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
Other Name: Trypanozoon RT-qPCR multiplex, SNP RT-qPCR, SHERLOCK |
- Specificity of serological field test for diagnosis of HAT during active screening in Côte d'Ivoire and Guinea [ Time Frame: 1 month ]Index tests: Bioline HAT 2.0 (Abbott, South Korea), HAT Sero-K-SeT (Coris BioConcept, Belgium), HAT 2.0 Sero-K-SeT (Coris BioConcept, Belgium), RDT DCN (USA), CATT/Tb gambiense (ITM Antwerp, Belgium). Reference test: parasitological confirmation by combined lymph and blood (mAECT) examination
- Specificity of serological field test for diagnosis of HAT during active screening in Côte d'Ivoire and Guinea, in function of malaria status [ Time Frame: 1 month ]Index tests: Bioline HAT 2.0 (Abbott, South Korea), HAT Sero-K-SeT (Coris BioConcept, Belgium), HAT 2.0 Sero-K-SeT (Coris BioConcept, Belgium), RDT DCN (USA), CATT/Tb gambiense (ITM Antwerp, Belgium). Reference test: parasitological confirmation by combined lymph and blood (mAECT) examination. The malaria status will be determined using an RDT detecting HRP2
- Specificity of immunologic and molecular laboratory tests for diagnosis of HAT in serological suspects [ Time Frame: 1 year ]Index tests: trypanolysis, ELISA/T.b.gambiense, g-iELISA, Trypanozoon RT-qPCR multiplex, SNP RT-qPCR, SHERLOCK. Reference test: parasitological confirmation by combined lymph and blood (mAECT) examination.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 10 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- at least 10 years old
- signed the informed consent form (in case of minor: parent or tutor signs informed consent form and minor signs ascent form)
Exclusion Criteria:
- severe anemia hindering blood sampling
- severe illness hindering obtention of informed consent (eg coma, cognitive deficiency etc)
- history of sleeping sickness
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05466630
| Contact: Veerle Lejon | +33467593950 | veerle.lejon@ird.fr | |
| Contact: Sylvain Bieler | +41 22 710 27 81 | sylvain.bieler@finddx.org |
| Côte D'Ivoire | |
| Université Jean Lorougnon Guédé de Daloa | Recruiting |
| Bonon, Côte D'Ivoire | |
| Contact: Martial N'Djetchi Kassi +225 07 47 14 13 30 ndjetchi2015@gmail.com | |
| Guinea | |
| Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de Santé, Division Prévention et Lutte contre la Maladie | Recruiting |
| Dubréka, Guinea | |
| Contact: Oumou Camara +224 666 734 930 oumicam@yahoo.fr | |
| Principal Investigator: | Martial N'Djetchi Kassi | Université Jean Lorougnon Guédé de Daloa | |
| Principal Investigator: | Oumou Camara | Programme National de lutte contre de la THA en Guinée |
| Responsible Party: | Veerle Lejon, Research Director, Institut de Recherche pour le Developpement |
| ClinicalTrials.gov Identifier: | NCT05466630 |
| Other Study ID Numbers: |
SpeSerTryp |
| First Posted: | July 20, 2022 Key Record Dates |
| Last Update Posted: | July 20, 2022 |
| Last Verified: | July 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | As part of the open data policy (FAIR data), the final database of the study will be deposited in the IRD's institutional depository "DataSud" and will be identified by a DOI. Metadata describing the database will be under open access. The database itself, containing personal health data, may be considered "sensitive", and will be under controlled access by a data access committee which will assess specific requests for data use. The partners who generated the data will remain the owners of the data. |
| Time Frame: | Data are estimated to be deposited about 1 year after the start of recruitment. Data will remain available as long as the study is showcased on datasud |
| Access Criteria: | Metadata will be public. Personal health data, may be considered "sensitive", will be under controlled access by a data access committee which will assess specific requests for data use. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Diagnosis |
|
Trypanosomiasis Trypanosomiasis, African Euglenozoa Infections Protozoan Infections |
Parasitic Diseases Infections Vector Borne Diseases |